Blog

Wesana Announces Second Quarter 2022 Financial Results

Aug 30 • 5 min read

Wesana Health Holdings Inc. (CSE: WESA | OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, has today announced its second quarter 2022 financial results. H1 2022 Highlights Received positive feedback from pre-Investigational New Drug (“IND”) meeting with U.S. Food and Drug Administration (“FDA”) on SANA-013…

Thailand is Reconsidering Magic Mushroom Laws

Aug 30 • 6 min read

The last few years have marked the resurgence of research into the medicinal properties of psychedelics, and there are a few key countries that are leading this effort. The US, Canada, and the Netherlands are where the majority of psychedelic companies are operating because their governments have been allowing research and showing interest in changing…

How Can the Future of Psychedelics Respect Its Past?: Mindshifting Moments #8

Aug 30 • 1 min read

Honoring Traditions Indigenous tribes and traditions have existed for longer than history could record them. With so much happening around psychedelics right now, it’s important we consider the ways that future use pays tribute to that rich history. In this edition of Mindshifting Moments, we answer the question “How can the future of psychedelics respect…

Wellbeing Subsidiary KGK Science Announces AKL No Objection Status for ProGo Branded Ingredient from FDA

Aug 29 • 4 min read

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (‘KGK’) provided regulatory guidance and expertise on behalf of its client, Hofseth…

PharmAla Biotech completes filing of Patent application for 6 MDMA analogs

Aug 29 • 4 min read

PharmAla Biotech (CSE: MDMA) is pleased to announce the filing of a key Patent Cooperation Treaty (PCT) application, containing 6 Novel Chemical Entities (NCEs). The application claims priority to, and benefit of a United States provisional patent application filed August 20, 2021. This PCT application disclosed novel compositions of MDMA and analogs thereof which may be used to alleviate…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548